InsiderTrades.com logo
Ryan Cohlhepp net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ryan Cohlhepp Biography and Net Worth

COO of Bicara Therapeutics

Ryan Cohlhepp brings to Bicara over 20 years of experience in the life sciences industry, driving early-stage drug development to commercial success. Prior to Bicara, Ryan was a founding executive of Rheos Medicines, an immuno-metabolism company launched by Third Rock Ventures. Previously, Ryan held multiple roles in both the R&D and Commercial organizations at Takeda including leading the company’s commercial oncology portfolio in the U.S. which included four approved compounds across both hematological and solid tumors.

An endurance athlete with a commitment to bringing transformative and life-extending therapies to cancer patients, he has worked with the Multiple Myeloma Research Foundation, having summitted the renowned 19,341 foot Uhuru Peak on Mount Kilimanjaro to encourage patient advocacy and raise funds for multiple myeloma research.

Ryan holds his Doctor of Pharmacy from Purdue University where he continues to hold an appointment on the Dean’s Advisory Council.

What is Ryan Cohlhepp's net worth?

The estimated net worth of Ryan Cohlhepp is at least $3.24 million as of January 22nd, 2026. Cohlhepp owns 210,164 shares of Bicara Therapeutics stock worth more than $3,240,729 as of February 20th. This net worth evaluation does not reflect any other investments that Cohlhepp may own. Additionally, Cohlhepp receives a salary of $660,000.00 as COO at Bicara Therapeutics. Learn More about Ryan Cohlhepp's net worth.

How old is Ryan Cohlhepp?

Cohlhepp is currently 48 years old. There are 4 older executives and no younger executives at Bicara Therapeutics. Learn More on Ryan Cohlhepp's age.

What is Ryan Cohlhepp's salary?

As the COO of Bicara Therapeutics Inc., Cohlhepp earns $660,000.00 per year. Learn More on Ryan Cohlhepp's salary.

How do I contact Ryan Cohlhepp?

The corporate mailing address for Cohlhepp and other Bicara Therapeutics executives is 116 Huntington Avenue, Suite 703, Boston, MA 02116, United States. Bicara Therapeutics can also be reached via phone at (617) 468-4219 and via email at [email protected]. Learn More on Ryan Cohlhepp's contact information.

Has Ryan Cohlhepp been buying or selling shares of Bicara Therapeutics?

In the last ninety days, Ryan Cohlhepp has sold $71,971.78 in Bicara Therapeutics stock. Most recently, Ryan Cohlhepp sold 3,828 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a transaction totalling $69,286.80. Following the completion of the sale, the chief operating officer now directly owns 210,164 shares of the company's stock, valued at $3,803,968.40. Learn More on Ryan Cohlhepp's trading history.

Who are Bicara Therapeutics' active insiders?

Bicara Therapeutics' insider roster includes Ryan Cohlhepp (COO), Ivan Hyep (CFO), Claire Mazumdar (CEO), and David Raben (Insider). Learn More on Bicara Therapeutics' active insiders.

Are insiders buying or selling shares of Bicara Therapeutics?

In the last year, insiders at the sold shares 19 times. They sold a total of 242,456 shares worth more than $4,466,154.60. The most recent insider tranaction occured on January, 22nd when COO Ryan Cohlhepp sold 3,828 shares worth more than $69,286.80. Insiders at Bicara Therapeutics own 15.5% of the company. Learn More about insider trades at Bicara Therapeutics.

Information on this page was last updated on 1/22/2026.

Ryan Cohlhepp Insider Trading History at Bicara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2026Sell3,828$18.10$69,286.80210,164View SEC Filing Icon  
1/15/2026Sell149$18.02$2,684.98213,992View SEC Filing Icon  
12/15/2025Sell12,500$18.68$233,500.00189,141View SEC Filing Icon  
11/21/2025Sell12,500$18.05$225,625.00193,641View SEC Filing Icon  
10/15/2025Sell12,500$18.16$227,000.00198,141View SEC Filing Icon  
10/7/2025Sell10,900$18.06$196,854.00202,641View SEC Filing Icon  
10/6/2025Sell39,600$18.06$715,176.00205,541View SEC Filing Icon  
See Full Table

Ryan Cohlhepp Buying and Selling Activity at Bicara Therapeutics

This chart shows Ryan Cohlhepp's buying and selling at Bicara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bicara Therapeutics Company Overview

Bicara Therapeutics logo
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $15.62
Low: $15.39
High: $16.68

50 Day Range

MA: $16.57
Low: $14.06
High: $18.48

2 Week Range

Now: $15.62
Low: $7.80
High: $19.71

Volume

882,486 shs

Average Volume

421,483 shs

Market Capitalization

$855.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A